“I am delighted to welcome Chris to the Relievant team. The addition of a seasoned financial executive is a key milestone in the company’s transition into a commercial organization," said Hykes. “Over his career, Chris has been instrumental in driving financial strategy and rapid commercial growth. His experience with successful public and private sector companies and strategic transactions will be invaluable to Relievant as the company enters its next phase of growth.”
Geyen brings 25 years of financial and executive leadership experience from the healthcare sector. He previously served as CFO of NeuWave Medical. After NeuWave’s acquisition by Johnson & Johnson in 2016, he continued on with J&J within the interventional oncology platform. Prior to NeuWave, Geyen served as CFO of Celleration, where he helped guide the business through the process of securing reimbursement on its way to being acquired by Alliqua BioMedical. He also served as CFO of Restore Medical, where he completed an initial public offering and subsequent acquisition by Medtronic plc, in addition to serving as CFO at Acorn Cardiovascular and Urologix. Geyen began his career with accounting firm EY (formerly Ernst & Young).
Geyen has a bachelor of arts degree in business administration and accounting from the University of St. Thomas, Minnesota and is a licensed certified public accountant (inactive).
Founded in 2006 and based in Sunnyvale, Calif., Relievant Medsystems develops new solutions for chronic lower back pain (CLBP). Relievant’s Intracept System delivers targeted energy into the spine and blocks the transmission of pain signals from the basivertebral nerve. This minimally invasive procedure provides orthopedic surgeons, neurological surgeons and interventionalists with a new way to provide clinically proven, lasting pain relief for CLBP. As with any surgical procedure, there are risks and considerations associated with the Intracept Procedure.